One hypothesis is that the AChE inhibitors act by enhancing neurotrophic factors, especially nerve growth factor (NGF), which affect key AD-associated pathophysiological processes in the basal forebrain, cortex, and hippocampus [20,63,64,65,66]. Here, ACHE is linked to Alzheimer disease.